Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Endocrinology

What Medications Are Used to Treat High Calcium in FHH1?

At a Glance

Most people with Familial Hypocalciuric Hypercalcemia Type 1 (FHH1) do not need daily medication to lower their blood calcium. In rare cases where calcium becomes dangerously high or causes severe symptoms, doctors may prescribe a calcimimetic drug called Cinacalcet.

In this answer

4 sections

01

When Is Medication Needed?

02

How Calcimimetics Work

03

Side Effects and Monitoring

04

Are Other Medications Used?

For most people living with Familial Hypocalciuric Hypercalcemia Type 1 (FHH1), taking a daily pill to lower blood calcium isn’t necessary. FHH1 is usually a benign condition, meaning the mildly elevated calcium levels don’t typically cause harm or symptoms [1][2]. As a result, doctors rarely prescribe medication for routine management [3]. Furthermore, standard surgical treatments for high calcium—like removing the parathyroid glands (parathyroidectomy)—are generally ineffective and should be avoided [4][5]. However, if your calcium levels become dangerously high or cause significant symptoms—which is quite rare—there are specific medications that can help.

When Is Medication Needed?

Doctors consider pharmacological management, or medication, only in rare, specific scenarios [6][7]. You might be a candidate for medication if:

  • You are highly symptomatic: You experience severe issues related to high calcium, such as extreme fatigue, confusion, or other complications. Conditions like pancreatitis can happen with severe high calcium, though this is exceptionally rare in standard FHH1 [8].
  • You experience metabolic stress: Sometimes severe physical illnesses or bodily trauma (not just everyday psychological stress) can spike calcium levels to dangerous extremes, prompting the need for intervention [9][8].

For these unusual situations, doctors turn to a class of drugs called calcimimetics, with the most common being an oral daily pill called Cinacalcet [10].

How Calcimimetics Work

To understand how a drug like Cinacalcet works, it helps to know what is happening in FHH1. In FHH1, a genetic mutation causes a defect in your calcium-sensing receptors (CaSR)—the “thermostats” in your body that monitor calcium levels. Because these receptors are faulty, they mistakenly believe your calcium is too low and signal the body to hold onto more calcium, driving your blood levels up.

Cinacalcet works as an allosteric modulator, meaning it binds directly to the faulty calcium-sensing receptors and changes their shape [10][11]. By doing this, the drug essentially bypasses the genetic defect and “manually” sensitizes the receptor to calcium [12][13].

Once the receptor is sensitized, it finally realizes the blood calcium is high and signals your parathyroid glands to stop releasing parathyroid hormone (PTH) [14][6]. This effectively turns down the calcium thermostat, resulting in lower blood calcium and lower PTH levels [15][16].

Side Effects and Monitoring

If you do need to take Cinacalcet, it is important to know that it comes with potential side effects. The most common side effects are gastrointestinal issues, such as nausea and vomiting [15]. Because the drug is very effective at lowering calcium, there is also a risk of over-correcting and dropping your calcium levels too low (hypocalcemia). To ensure your safety, your doctor will require regular blood tests—often every few weeks when starting the medication—to closely monitor your calcium and PTH levels and adjust the dose as needed [17][18].

Are Other Medications Used?

For the routine management of FHH1, there is no established role for other bone medications like bisphosphonates or denosumab, which are sometimes used to treat other types of high calcium [8][1]. In extreme emergency cases of severe hypercalcemia, intensive hospital treatments including intravenous bisphosphonates or calcitonin may be used alongside Cinacalcet to quickly stabilize a patient [8].

However, for the vast majority of patients with FHH1, the best approach is careful monitoring without any medication, avoiding unnecessary risks and side effects [1][2]. “Careful monitoring” typically means checking your blood calcium and PTH levels once a year or at an interval specifically recommended by your endocrinologist, rather than taking daily action [2].

Common questions in this guide

Do I need to take medication to lower my calcium if I have FHH1?
In most cases, routine medication is not necessary because FHH1 is typically a benign condition. Your body is usually perfectly fine with a slightly higher calcium level, and careful monitoring with regular blood tests is the standard approach.
Should I get parathyroid surgery to fix my high calcium?
No, standard surgical treatments like parathyroidectomy are generally ineffective for FHH1 and should be avoided. The high calcium in FHH1 is caused by a genetic receptor defect, not a localized parathyroid tumor, so removing the glands does not fix the root issue.
When would a doctor prescribe Cinacalcet for FHH1?
Your endocrinologist might prescribe a calcimimetic like Cinacalcet if your calcium levels become dangerously high, or if you develop severe symptoms like extreme fatigue or confusion. This usually only happens during times of severe physical illness or bodily trauma.
How does Cinacalcet lower blood calcium levels?
Cinacalcet works by binding directly to the faulty calcium-sensing receptors in your body, bypassing the FHH1 genetic defect. This sensitizes the receptors so they finally realize your blood calcium is too high, signaling your glands to stop producing excess parathyroid hormone.
What are the side effects of taking Cinacalcet?
The most common side effects are gastrointestinal issues, such as nausea and vomiting. Because the drug is very effective, it can also cause your blood calcium to drop too low, which is why frequent blood tests are required when starting the medication.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are my calcium levels at a point where we should consider a calcimimetic, or am I safe to just monitor?
  2. 2.How often should we check my blood calcium and parathyroid hormone (PTH) levels, and is a yearly check sufficient for my specific case?
  3. 3.If I experience a severe physical illness or bodily trauma, what signs should I watch for that might indicate a dangerous spike in my calcium?
  4. 4.What side effects and blood monitoring schedule should I expect if we do decide to start a medication like Cinacalcet?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Water Pills or Lithium Affect FHH Urine Tests?High Calcium: How Do Doctors Tell FHH1 From Cancer?How Does Vitamin D Deficiency Affect FHH1 Testing?Does My Baby Need Calcium Monitoring if I Have FHH1?High Calcium After Parathyroid Surgery: Could It Be FHH1?What Are the Long-Term Complications of FHH1?What is Neonatal Severe Hyperparathyroidism (NSHPT)?What's the Difference Between FHH Type 1, 2, and 3?

References

References (18)
  1. 1

    A novel homozygous mutation of the calcium-sensing receptor gene associated with apparent autosomal recessive inheritance of familial hypocalciuric hypercalcemia.

    Li N, Li X, Ni XL, et al.

    Chinese medical journal 2021; (134(15)):1869-1871 doi:10.1097/CM9.0000000000001568.

    PMID: 34397587
  2. 2

    Nephrotic Syndrome Complicated with Familial Hypocalciuric Hypercalcemia in an Infant: A Case Report and Comprehensive Literature Review.

    Yu M, Xue M, Fan X, et al.

    Alternative therapies in health and medicine 2024;.

    PMID: 38702153
  3. 3

    A novel homozygous c.301T > C, p.Y101H variant in the GNA11 gene is implicated in familial hypocalciuric hypercalcemia type 2 in a proband with the heterozygous variant present in mother and father - A case report.

    Koca SB, Balta B

    Scandinavian journal of clinical and laboratory investigation 2025; (85(8)):670-674 doi:10.1080/00365513.2025.2588772.

    PMID: 41240382
  4. 4

    Novel mutations of the calcium-sensing receptor impede differential diagnosis of primary hyperparathyroidism and familial hypocalciuric hypercalcemia.

    Bhangu JS, Baumgartner-Parzer S, Hargitai L, et al.

    Gland surgery 2022; (11(1)):12-22 doi:10.21037/gs-21-577.

    PMID: 35242665
  5. 5

    Multiple endocrine neoplasia phenocopy revealed as a co-occurring neuroendocrine tumor and familial hypocalciuric hypercalcemia type 3.

    Hovden S, Jespersen ML, Nissen PH, et al.

    Clinical case reports 2016; (4(10)):922-927 doi:10.1002/ccr3.657.

    PMID: 27761240
  6. 6

    Familial hypocalciuric hypercalcemia and related disorders.

    Lee JY, Shoback DM

    Best practice & research. Clinical endocrinology & metabolism 2018; (32(5)):609-619 doi:10.1016/j.beem.2018.05.004.

    PMID: 30449544
  7. 7

    Case Report: Severe Neonatal Course in Paternally Derived Familial Hypocalciuric Hypercalcemia.

    Höppner J, Lais S, Roll C, et al.

    Frontiers in endocrinology 2021; (12()):700612 doi:10.3389/fendo.2021.700612.

    PMID: 34659108
  8. 8

    Severe Symptomatic Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia.

    Kurian R, Madegowda Chandrashekar G, Antony MA, et al.

    Cureus 2021; (13(11)):e20057 doi:10.7759/cureus.20057.

    PMID: 34993031
  9. 9

    Cinacalcet therapy in a child with novel homozygous CASR p.Glu353Lys mutation causing familial hypocalciuric hypercalcemia type 1: case report and review of the literature.

    Koca SB

    The Turkish journal of pediatrics 2023; (65(5)):853-861.

    PMID: 37853976
  10. 10

    Cinacalcet for Symptomatic Hypercalcemia Caused by AP2S1 Mutations.

    Howles SA, Hannan FM, Babinsky VN, et al.

    The New England journal of medicine 2016; (374(14)):1396-1398 doi:10.1056/NEJMc1511646.

    PMID: 27050234
  11. 11

    Asymmetric activation of the calcium-sensing receptor homodimer.

    Gao Y, Robertson MJ, Rahman SN, et al.

    Nature 2021; (595(7867)):455-459 doi:10.1038/s41586-021-03691-0.

    PMID: 34194040
  12. 12

    Heterozygous Mutation (Q459R) in the Calcium-Sensing Receptor Gene Causes Familial Hypocalciuric Hypercalcemia 1 (FHH1).

    Boisen IM, Mos I, Lerche-Black EM, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(4)) doi:10.1210/clinem/dgz205.

    PMID: 32160303
  13. 13

    Clinical Pharmacokinetics and Pharmacodynamics of Etelcalcetide, a Novel Calcimimetic for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis.

    Wu B, Melhem M, Subramanian R, et al.

    Journal of clinical pharmacology 2018; (58(6)):717-726 doi:10.1002/jcph.1090.

    PMID: 29534286
  14. 14

    Two Cases of Symptomatic Familial Hypocalciuric Hypercalcemia: Treatment Response to Calcimimetic Therapy.

    Shakesprere J, Shafiq R, Madahar I, et al.

    JCEM case reports 2024; (2(6)):luae096 doi:10.1210/jcemcr/luae096.

    PMID: 38832006
  15. 15

    Successful use of cinacalcet monotherapy in the management of siblings with homozygous calcium-sensing receptor mutation.

    Wade L, Aindow A, Isherwood L, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2022; (35(4)):549-556 doi:10.1515/jpem-2021-0632.

    PMID: 35073615
  16. 16

    Cinacalcet therapy in an infant with an R185Q calcium-sensing receptor mutation causing hyperparathyroidism: a case report and review of the literature.

    Forman TE, Niemi AK, Prahalad P, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2019; (32(3)):305-310 doi:10.1515/jpem-2018-0307.

    PMID: 30730839
  17. 17

    Novel homozygous inactivating mutation of the calcium-sensing receptor gene in neonatal severe hyperparathyroidism responding to cinacalcet therapy: A case report and literature review.

    Sun X, Huang L, Wu J, et al.

    Medicine 2018; (97(45)):e13128 doi:10.1097/MD.0000000000013128.

    PMID: 30407334
  18. 18

    Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience.

    Bernardor J, Flammier S, Salles JP, et al.

    Frontiers in pediatrics 2022; (10()):926986 doi:10.3389/fped.2022.926986.

    PMID: 36090548

This page explains potential medication options for managing FHH1 for educational purposes only. Always consult your endocrinologist before starting or changing any treatment for high calcium.

Get notified when new evidence is published on Familial hypocalciuric hypercalcemia type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.